|
1
|
Kariya Y and Kariya Y: Osteopontin in
cancer: Mechanisms and therapeutic targets. Int J Transl Med.
2:419–447. 2022.
|
|
2
|
Liu X, Fang J, Huang S, Wu X, Xie X, Wang
J, Liu F, Zhang M, Peng Z and Hu N: Tumor-on-a-chip: From
bioinspired design to biomedical application. Microsyst Nanoeng.
7:502021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
4
|
Yang M, Cui M, Sun Y, Liu S and Jiang W:
Mechanisms, combination therapy, and biomarkers in cancer
immunotherapy resistance. Cell Commun Signa. 22:3382024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toledo B, Deiana C, Scianò F, Brandi G,
Marchal JA, Perán M and Giovannetti E: Treatment resistance in
pancreatic and biliary tract cancer: Molecular and clinical
pharmacology perspectives. Expert Rev Clin Pharmacol. 17:323–347.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Z, Bao C, Jiang L, Wang S, Wang K,
Lu C and Fang H: When cancer drug resistance meets metabolomics
(bulk, single-cell and/or spatial): Progress, potential, and
perspective. Front Oncol. 12:10542332022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yim A, Smith C and Brown AM:
Osteopontin/secreted phosphoprotein-1 harnesses glial-, immune-,
and neuronal cell ligand-receptor interactions to sense and
regulate acute and chronic neuroinflammation. Immunol Rev.
311:224–233. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sodek J, Ganss B and McKee MD:
Osteopontin. Crit Rev Oral Biol Med. 11:279–303. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Senger DR, Wirth DF and Hynes RO:
Transformed mammalian cells secrete specific proteins and
phosphoproteins. Cell. 16:885–893. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bastos ACSF, Blunck CB, Emerenciano M and
Gimba ERP: Osteopontin and their roles in hematological
malignancies: Splice variants on the new avenues. Cancer Lett.
408:138–143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gimba ER and Tilli TM: Human osteopontin
splicing isoforms: Known roles, potential clinical applications and
activated signaling pathways. Cancer Lett. 331:11–17. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jia Q, Ouyang Y, Yang Y, Yao S, Chen X and
Hu Z: Osteopontin: A novel therapeutic target for respiratory
diseases. Lung. 202:25–39. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao H, Chen Q, Alam A, Cui J, Suen KC,
Soo AP, Eguchi S, Gu J and Ma D: The role of osteopontin in the
progression of solid organ tumour. Cell Death Dis. 9:3562018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Panda VK, Mishra B, Nath AN, Butti R,
Yadav AS, Malhotra D, Khanra S, Mahapatra S, Mishra P, Swain B, et
al: Osteopontin: A key multifaceted regulator in tumor progression
and immunomodulation. Biomedicines. 12:15272024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mi Z, Guo H, Russell MB, Liu Y, Sullenger
BA and Kuo PC: RNA aptamer blockade of osteopontin inhibits growth
and metastasis of MDA-MB231 breast cancer cells. Mol Ther.
17:153–161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar V, Behera R, Lohite K, Karnik S and
Kundu GC: p38 kinase is crucial for osteopontin-induced furin
expression that supports cervical cancer progression. Cancer Res.
70:10381–10391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zagani R, Hamzaoui N, Cacheux W, de
Reyniès A, Terris B, Chaussade S, Romagnolo B, Perret C and
Lamarque D: Cyclooxygenase-2 inhibitors down-regulate osteopontin
and Nr4A2-new therapeutic targets for colorectal cancers.
Gastroenterology. 137:1358–1366.e1-e3. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Standal T, Borset M and Sundan A: Role of
osteopontin in adhesion, migration, cell survival and bone
remodeling. Exp Oncol. 26:179–184. 2004.PubMed/NCBI
|
|
19
|
Briones-Orta MA, Avendaño-Vázquez SE,
Aparicio-Bautista DI, Coombes JD, Weber GF and Syn WK: Osteopontin
splice variants and polymorphisms in cancer progression and
prognosis. Biochim Biophys Acta Rev Cancer. 1868:93–108.A. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hao C, Cui Y, Owen S, Li W, Cheng S and
Jiang WG: Human osteopontin: Potential clinical applications in
cancer (review). Int J Mol Med. 39:1327–1337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Regan A and Berman JS: Osteopontin: A
key cytokine in cell-mediated and granulomatous inflammation. Int J
Exp Pathol. 81:373–390. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mirzaei A, Mohammadi S, Ghaffari SH,
Yaghmaie M, Vaezi M, Alimoghaddam K and Ghavamzadeh A: Osteopontin
b and c splice isoforms in leukemias and solid tumors: Angiogenesis
alongside chemoresistance. Asian Pac J Cancer Prev. 19:615–623.
2018.PubMed/NCBI
|
|
23
|
Castello LM, Raineri D, Salmi L, Clemente
N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P,
Cantaluppi V, et al: Osteopontin at the crossroads of inflammation
and tumor progression. Mediators Inflamm. 2017:40490982017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lamort AS, Giopanou I, Psallidas I and
Stathopoulos GT: Osteopontin as a link between inflammation and
cancer: The thorax in the spotlight. Cells. 8:8152019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schytte GN, Christensen B, Bregenov I,
Kjøge K, Scavenius C, Petersen SV, Enghild JJ and Sørensen ES:
FAM20C phosphorylation of the RGDSVVYGLR motif in osteopontin
inhibits interaction with the αvβ3 integrin. J Cell Biochem.
121:4809–4818. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Clark EA and Brugge JS: Integrins and
signal transduction pathways: The road taken. Science. 268:233–239.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang KX and Denhardt DT: Osteopontin: Role
in immune regulation and stress responses. Cytokine Growth Factor
Rev. 19:333–345. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yokosaki Y, Matsuura N, Sasaki T, Murakami
I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y and
Sheppard D: The integrin alpha(9)beta(1) binds to a novel
recognition sequence (SVVYGLR) in the thrombin-cleaved
amino-terminal fragment of osteopontin. J Biol Chem.
274:36328–36334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ito K, Kon S, Nakayama Y, Kurotaki D,
Saito Y, Kanayama M, Kimura C, Diao H, Morimoto J, Matsui Y and
Uede T: The differential amino acid requirement within osteopontin
in alpha4 and alpha9 integrin-mediated cell binding and migration.
Matrix Biol. 28:11–19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maeda N and Maenaka K: The roles of
matricellular proteins in oncogenic virus-induced cancers and their
potential utilities as therapeutic targets. Int J Mol Sci.
17:21982017. View Article : Google Scholar
|
|
31
|
Denhardt DT and Guo X: Osteopontin: A
protein with diverse functions. FASEB J. 7:1475–1482. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kazanecki CC, Uzwiak DJ and Denhardt DT:
Control of osteopontin signaling and function by post-translational
phosphorylation and protein folding. J Cell Biochem. 102:912–924.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bellahcène A, Castronovo V, Ogbureke KUE,
Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked
glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat
Rev Cancer. 8:212–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dalal S, Zha Q, Daniels CR, Steagall RJ,
Joyner WL, Gadeau AP, Singh M and Singh K: Osteopontin stimulates
apoptosis in adult cardiac myocytes via the involvement of CD44
receptors, mitochondrial death pathway, and endoplasmic reticulum
stress. Am J Physiol Heart Circ Physiol. 306:H1182–H1191. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miyazaki K, Okada Y, Yamanaka O, Kitano A,
Ikeda K, Kon S, Uede T, Rittling SR, Denhardt DT, Kao WW and Saika
S: Corneal wound healing in an osteopontin-deficient mouse. Invest
Ophth Vis Sci. 49:1367–1375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei J, Marisetty A, Schrand B,
Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X,
Caruso H, et al: Osteopontin mediates glioblastoma-associated
macrophage infiltration and is a potential therapeutic target. J
Clin Invest. 129:137–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun C, Rahman MSU, Enkhjargal B, Peng J,
Zhou K, Xie Z, Wu L, Zhang T, Zhu Q, Tang J, et al: Osteopontin
modulates microglial activation states and attenuates inflammatory
responses after subarachnoid hemorrhage in rats. Exp Neurol.
371:1145852024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao Y, Huang Z, Gao L, Ma H and Chang R:
Osteopontin/SPP1: A potential mediator between immune cells and
vascular calcification. Front Immunol. 15:13955962024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang S, Hu H, Li M, Zhang K, Wu Q, Liu X,
Wu L, Yu B and Chen X: OPN promotes pro-inflammatory cytokine
expression via ERK/JNK pathway and M1 macrophage polarization in
rosacea. Front Immunol. 14:12859512024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao L, Wang Z, Tan Y, Ma J, Huang W,
Zhang X, Jin C, Zhang T, Liu W and Yang YG: IL-17A/CEBPβ/OPN/LYVE-1
axis inhibits anti-tumor immunity by promoting tumor-associated
tissue-resident macrophages. Cell Rep. 43:1150392024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
He Z, Shen S, Yi Y, Ren L, Tao H, Wang F
and Jia Y: CD31 promotes diffuse large B-cell lymphoma metastasis
by upregulating OPN through the AKT pathway and inhibiting CD8+ T
cells through the mTOR pathway. Am J Transl Res. 15:2656–2675.
2023.PubMed/NCBI
|
|
42
|
Ding W, Deng S, Wang Z, Chen X, Xu Z,
Zhong J, Wu X, Lin R, Ye S, Li C and Li H: CD163+ macrophages drive
rapid pulmonary fibrosis via osteopontin secretion. Int
Immunopharmacol. 161:1149762025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang H, Gan Z, Wang Y, Hu D, Zhang L, Ye F
and Duan P: A noninvasive menstrual Blood-based diagnostic platform
for endometriosis using digital droplet Enzyme-linked immunosorbent
assay and Single-cell RNA sequencing. Research (Wash DC).
8:06522025.PubMed/NCBI
|
|
44
|
Crawford HC, Matrisian LM and Liaw L:
Distinct roles of osteopontin in host defense activity and tumor
survival during squamous cell carcinoma progression in vivo. Cancer
Res. 58:5206–5215. 1998.PubMed/NCBI
|
|
45
|
Icer MA and Gezmen-Karadag M: The multiple
functions and mechanisms of osteopontin. Clin Biochem. 59:17–24.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Steitz SA, Speer MY, McKee MD, Liaw L,
Almeida M, Yang H and Giachelli CM: Osteopontin inhibits mineral
deposition and promotes regression of ectopic calcification. Am J
Pathol. 161:2035–2046. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Giachelli CM and Steitz S: Osteopontin: A
versatile regulator of inflammation and biomineralization. Matrix
Biol. 19:615–622. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McKee MD, Pedraza CE and Kaartinen MT:
Osteopontin and wound healing in bone. Cells Tissues Organs.
194:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ishijima M, Rittling SR, Yamashita T,
Tsuji K, Kurosawa H, Nifuji A, Denhardt DT and Noda M: Enhancement
of osteoclastic bone resorption and suppression of osteoblastic
bone formation in response to reduced mechanical stress do not
occur in the absence of osteopontin. J Exp Med. 193:399–404. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Miragliotta V, Pirone A, Donadio E, Abramo
F, Ricciardi MP and Theoret CL: Osteopontin expression in healing
wounds of horses and in human keloids. Equine Vet J. 48:72–77.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wen Y, Feng D, Wu H, Liu W, Li H, Wang F,
Xia Q, Gao WQ and Kong X: Defective initiation of liver
regeneration in osteopontin-deficient mice after partial
hepatectomy due to insufficient activation of IL-6/Stat3 pathway.
Int J Biol Sci. 11:1236–1247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ström A, Franzén A, Wängnerud C, Knutsson
AK, Heinegård D and Hultgårdh-Nilsson A: Altered vascular
remodeling in osteopontin-deficient atherosclerotic mice. J Vasc
Res. 41:314–322. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Khuri FR, Shin DM, Glisson BS, Lippman SM
and Hong WK: Treatment of patients with recurrent or metastatic
squamous cell carcinoma of the head and neck: Current status and
future directions. Semin Oncol. 27:25–33. 2000.PubMed/NCBI
|
|
54
|
Peng Y, Feng W, Huang H, Chen Y and Yang
SY: Macrophage-targeting antisenescence nanomedicine enables
in-situ NO induction for gaseous and antioxidative atherosclerosis
intervention. Bioact Mater. 48:294–312. 2025.PubMed/NCBI
|
|
55
|
Lomashvili KA, Cobbs S, Hennigar RA,
Hardcastle KI and O'Neill WC: Phosphate-induced vascular
calcification: Role of pyrophosphate and osteopontin. J Am Soc
Nephrol. 15:1392–1401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Speer MY, McKee MD, Guldberg RE, Liaw L,
Yang HY, Tung E, Karsenty G and Giachelli CM: Inactivation of the
osteopontin gene enhances vascular calcification of matrix Gla
Protein-deficient mice: Evidence for osteopontin as an inducible
inhibitor of vascular calcification in vivo. J Exp Med.
196:1047–1055. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bandopadhyay M, Bulbule A, Butti R,
Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D,
Kumar S, et al: Osteopontin as a therapeutic target for cancer.
Expert Opin Ther Targets. 18:883–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chambers AF, Wilson SM, Kerkvliet N,
O'Malley FP, Harris JF and Casson AG: Osteopontin expression in
lung cancer. Lung Cancer. 15:311–323. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gotoh M, Sakamoto M, Kanetaka K, Chuuma M
and Hirohashi S: Overexpression of osteopontin in hepatocellular
carcinoma. Pathol Int. 52:19–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cook AC, Tuck AB, McCarthy S, Turner JG,
Irby RB, Bloom GC, Yeatman TJ and Chambers AF: Osteopontin induces
multiple changes in gene expression that reflect the six ‘hallmarks
of cancer’ in a model of breast cancer progression. Mol Carcinog.
43:225–236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Moorman HR, Poschel D, Klement JD, Lu C,
Redd PS and Liu K: Osteopontin: A key regulator of tumor
progression and immunomodulation. Cancers (Basel). 12:33792020.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kariya Y, Oyama M, Kariya Y and Hashimoto
Y: Phosphorylated osteopontin secreted from cancer cells induces
cancer cell motility. Biomolecules. 11:13232021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Klement JD, Paschall AV, Redd PS, Ibrahim
ML, Lu C, Yang D, Celis E, Abrams SI, Ozato K and Liu K: An
osteopontin/CD44 immune checkpoint controls CD8+ T cell activation
and tumor immune evasion. J Clin Invest. 128:5549–5560. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cao J, Li J, Sun L, Qin T, Xiao Y, Chen K,
Qian W, Duan W, Lei J, Ma J, et al: Hypoxia-driven paracrine
osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell
epithelial-mesenchymal transition and cancer stem cell-like
properties by modulating forkhead box protein M1. Mol Oncol.
13:228–245. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qian J, LeSavage BL, Hubka KM, Ma C,
Natarajan S, Eggold JT, Xiao Y, Fuh KC, Krishnan V, Enejder A, et
al: Cancer-associated mesothelial cells promote ovarian cancer
chemoresistance through paracrine osteopontin signaling. J Clin
Invest. 131:e1461862021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Huang R, Quan Y, Chen JH, Wang TF, Xu M,
Ye M, Yuan H, Zhang CJ, Liu XJ and Min ZJ: Osteopontin promotes
cell migration and invasion, and inhibits apoptosis and autophagy
in colorectal cancer by activating the p38 MAPK signaling pathway.
Cell Physiol Biochem. 41:1851–1864. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ahmed M, Sottnik JL, Dancik GM, Sahu D,
Hansel DE, Theodorescu D and Schwartz MA: An osteopontin/CD44 Axis
in RhoGDI2-Mediated metastasis suppression. Cancer Cell.
30:432–443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sun C, Enkhjargal B, Reis C, Zhou KR, Xie
ZY, Wu LY, Zhang TY, Zhu QQ, Tang JP, Jiang XD and Zhang JH:
Osteopontin attenuates early brain injury through regulating
autophagy-apoptosis interaction after subarachnoid hemorrhage in
rats. Cns Neurosci Ther. 25:1162–1172. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wei R, Wong JPC and Kwok HF: Osteopontin-a
promising biomarker for cancer therapy. J Cancer. 8:2173–2183.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J,
Li K, Tong X, Dai J, Yao S, et al: Down-regulation of osteopontin
suppresses growth and metastasis of hepatocellular carcinoma via
induction of apoptosis. Gastroenterology. 135:956–968. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fedarko NS, Fohr B, Robey PG, Young MF and
Fisher LW: Factor H binding to bone sialoprotein and osteopontin
enables tumor cell evasion of complement-mediated attack. J Biol
Chem. 275:16666–16672. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhou J, Chen X, Zhou P, Sun X, Chen Y, Li
M, Chu Y, Zhou J, Hu X, Luo Y, et al: Osteopontin is required for
the maintenance of leukemia stem cells in acute myeloid leukemia.
Biochem Biophys Res Commun. 600:29–34. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen Q, Shou P, Zhang L, Xu C, Zheng C,
Han Y, Li W, Huang Y, Zhang X, Shao C, et al: An
osteopontin-integrin interaction plays a critical role in directing
adipogenesis and osteogenesis by mesenchymal stem cells. Stem
Cells. 32:327–337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Irby RB, Mccarthy SM and Yeatman TJ:
Osteopontin regulates multiple functions contributing to human
colon cancer development and progression. Clin Exp Metastas.
21:515–523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Denhardt DT, Mistretta D, Chambers AF,
Krishna S, Porter JF, Raghuram S and Rittling SR: Transcriptional
regulation of osteopontin and the metastatic phenotype: Evidence
for a Ras-activated enhancer in the human OPN promoter. Clin Exp
Metastas. 20:77–84. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kale S, Raja R, Thorat D, Soundararajan G,
Patil TV and Kundu GC: Osteopontin signaling upregulates
cyclooxygenase-2 expression in tumor-associated macrophages leading
to enhanced angiogenesis and melanoma growth via α9β1 integrin.
Oncogene. 33:2295–2306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Mi Z, Guo H, Wai PY, Gao C and Kuo PC:
Integrin-linked kinase regulates osteopontin-dependent MMP-2 and
uPA expression to convey metastatic function in murine mammary
epithelial cancer cells. Carcinogenesis. 27:1134–1145. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wai PY and Kuo PC: The role of osteopontin
in tumor metastasis. J Surg Res. 121:228–241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gupta A, Zhou C and Chellaiah M:
Osteopontin and MMP9: Associations with VEGF expression/secretion
and angiogenesis in PC3 prostate cancer cells. Cancers (Basel).
5:617–638. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fukusada S, Shimura T, Natsume M,
Nishigaki R, Okuda Y, Iwasaki H, Sugimura N, Kitagawa M, Katano T,
Tanaka M, et al: Osteopontin secreted from obese adipocytes
enhances angiogenesis and promotes progression of pancreatic ductal
adenocarcinoma in obesity. Cell Oncol. 45:229–244. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wei R, Liu S, Zhang S, Min L and Zhu S:
Cellular and extracellular components in tumor microenvironment and
their application in early diagnosis of cancers. Anal Cell Pathol
(Amst). 2020:62837962020.PubMed/NCBI
|
|
83
|
Tan Y, Zhao L, Yang YG and Liu W: The role
of osteopontin in tumor progression through tumor-associated
macrophages. Front Oncol. 12:9532832022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Shao L, Zhang B, Wang L, Wu L, Kan Q and
Fan K: MMP-9-cleaved osteopontin isoform mediates tumor immune
escape by inducing expansion of myeloid-derived suppressor cells.
Biochem Biophys Res Commun. 493:1478–1484. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kariya Y, Oyama M, Hashimoto Y, Gu J and
Kariya Y: β4-integrin/PI3K signaling promotes tumor progression
through the galectin-3-N-glycan complex. Mol Cancer Res.
16:1024–1034. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Butti R, Kumar TVS, Nimma R, Banerjee P,
Kundu IG and Kundu GC: Osteopontin signaling in shaping tumor
microenvironment conducive to malignant progression. Adv Exp Med
Biol. 1329:419–441. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Rogers MP, Kothari A, Read M, Kuo PC and
Mi Z: Maintaining myofibroblastic-like cancer-associated
fibroblasts by cancer stemness signal transduction feedback loop.
Cureus. 14:e293542022.PubMed/NCBI
|
|
88
|
Leung LL, Myles T and Morser J: Thrombin
cleavage of osteopontin and the host anti-tumor immune response.
Cancers. 15:34802023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yan Z, Hu X, Tang B and Deng F: Role of
osteopontin in cancer development and treatment. Heliyon.
9:e210552023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Rangaswami H, Bulbule A and Kundu GC:
Osteopontin: Role in cell signaling and cancer progression. Trends
Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Abdelrahman KS, Hassan HA, Abdel-Aziz SA,
Marzouk AA, Narumi A, Konno H and Abdel-Aziz M: JNK signaling as a
target for anticancer therapy. Pharmacol Rep. 73:405–434. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shi L and Wang X: Role of osteopontin in
lung cancer evolution and heterogeneity. Semin Cell Dev Biol.
64:40–47. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Iida T, Wagatsuma K, Hirayama D and Nakase
H: Is osteopontin a friend or foe of cell apoptosis in inflammatory
gastrointestinal and liver diseases? Int J Mol Sci. 19:72017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Katoh M: Multi-layered prevention and
treatment of chronic inflammation, organ fibrosis and cancer
associated with canonical WNT/β-catenin signaling activation
(review). Int J Mol Med. 42:713–725. 2018.PubMed/NCBI
|
|
95
|
Bastos ACSDF, Gomes AVP, Silva GR,
Emerenciano M, Ferreira LB and Gimba ERP: The intracellular and
secreted sides of osteopontin and their putative physiopathological
roles. Int J Mol Sci. 24:29422023. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Berge G, Pettersen S, Grotterød I, Bettum
IJ, Boye K and Mælandsmo GM: Osteopontin-an important downstream
effector of S100A4-mediated invasion and metastasis. Int J Cancer.
129:780–790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Amilca-Seba K, Sabbah M, Larsen AK and
Denis JA: Osteopontin as a regulator of colorectal cancer
progression and its clinical applications. Cancers. 13:37932021.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hao C, Lane J and Jiang WG: Osteopontin
and cancer: Insights into its role in drug resistance.
Biomedicines. 11:1972023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Moldogazieva NT, Mokhosoev IM, Zavadskiy
SP and Terentiev AA: Proteomic profiling and artificial
intelligence for hepatocellular carcinoma translational medicine.
Biomedicines. 9:1592021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Messex JK, Byrd CJ, Thomas MU and Liou GY:
Macrophages cytokine Spp1 increases growth of prostate
intraepithelial neoplasia to promote prostate tumor progression.
Int J Mol Sci. 23:42472022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Insua-Rodríguez J, Pein M, Hongu T, Meier
J, Descot A, Lowy CM, De Braekeleer E, Sinn HP, Spaich S, Sütterlin
M, et al: Stress signaling in breast cancer cells induces matrix
components that promote chemoresistant metastasis. EMBO Mol Med.
10:e90032018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Li NY, Weber CE, Wai PY, Cuevas BD, Zhang
J, Kuo PC and Mi Z: An MAPK-dependent pathway induces
epithelial-mesenchymal transition via twist activation in human
breast cancer cell lines. Surgery. 154:404–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte
G, Mazzarino MC, et al: Mutations and deregulation of
ras/raf/MEK/ERK and PI3K/PTEN/akt/mTOR cascades which alter therapy
response. Oncotarget. 3:954–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Yang YF, Chang YC, Jan YH, Yang CJ, Huang
MS and Hsiao M: Squalene synthase promotes the invasion of lung
cancer cells via the osteopontin/ERK pathway. Oncogenesis.
9:782020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Chernaya G, Mikhno N, Khabalova T,
Svyatchenko S, Mostovich L, Shevchenko S and Gulyaeva L: The
expression profile of integrin receptors and osteopontin in thyroid
malignancies varies depending on the tumor progression rate and
presence of BRAF V600E mutation. Surg Oncol. 27:702–708. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL,
Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, et al: Lentiviral-mediated
miRNA against osteopontin suppresses tumor growth and metastasis of
human hepatocellular carcinoma. Hepatology. 48:1834–1842. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lin YH and Yang-Yen HF: The
osteopontin-CD44 survival signal involves activation of the
phosphatidylinositol 3-kinase/akt signaling pathway. J Biol Chem.
276:46024–46030. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhang H, Guo M, Chen JH, Wang Z, Du XF,
Liu PX and Li WH: Osteopontin knockdown inhibits αv,β3
integrin-induced cell migration and invasion and promotes apoptosis
of breast cancer cells by inducing autophagy and inactivating the
PI3K/akt/mTOR pathway. Cell Physiol Biochem. 33:991–1002. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang
A, Du W, Zeng Y, Zhu J, Liu Z and Huang JA: Abnormally activated
OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI
resistance in EGFR mutant Non-small-cell lung cancer. J Hematol
Oncol. 13:1692020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hui T, Sørensen ES and Rittling SR:
Osteopontin binding to the alpha 4 integrin requires highest
affinity integrin conformation, but is independent of
Post-translational modifications of osteopontin. Matrix Biol.
41:19–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wu Q, Li L, Miao C, Hasnat M, Sun L, Jiang
Z and Zhang L: Osteopontin promotes hepatocellular carcinoma
progression through inducing JAK2/STAT3/NOX1-mediated ROS
production. Cell Death Dis. 13:3412022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Behera R, Kumar V, Lohite K, Karnik S and
Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin
promotes tumor growth in human breast cancer cells. Carcinogenesis.
31:192–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Cao L, Fan X, Jing W, Liang Y, Chen R, Liu
Y, Zhu M, Jia R, Wang H, Zhang X, et al: Osteopontin promotes a
cancer stem cell-like phenotype in hepatocellular carcinoma cells
via an integrin-NF-κB-HIF-1α pathway. Oncotarget. 6:6627–6640.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chen B, Liang S, Guo H, Xu L, Li J and
Peng J: OPN promotes cell proliferation and invasion through NF-κB
in human esophageal squamous cell carcinoma. Genet Res (Camb).
2022:31548272022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Saurav S, Karfa S, Vu T, Liu Z, Datta A,
Manne U, Samuel T and Datta PK: Overcoming irinotecan resistance by
targeting its downstream signaling pathways in colon cancer.
Cancers (Basel). 16:34912024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Graessmann M, Berg B, Fuchs B, Klein A and
Graessmann A: Chemotherapy resistance of mouse WAP-SVT/t breast
cancer cells is mediated by osteopontin, inhibiting apoptosis
downstream of caspase-3. Oncogene. 26:2840–2850. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Yong HY, Koh MS and Moon A: The p38 MAPK
inhibitors for the treatment of inflammatory diseases and cancer.
Expert Opin Investig Drugs. 18:1893–1905. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Yu X, Du Y, Liang S, Zhang N, Jing S, Sui
L, Kong Y, Dong M and Kong H: OPN up-regulated proliferation and
invasion of head and neck squamous cell carcinoma through the
p38MAPK signaling pathway. Oral Surg Oral Med Oral Pathol Oral
Radiol. 136:70–79. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Pang H, Cai L, Yang Y, Chen X, Sui G and
Zhao C: Knockdown of osteopontin chemosensitizes MDA-MB-231 cells
to cyclophosphamide by enhancing apoptosis through activating p38
MAPK pathway. Cancer Biother Radiopharm. 26:165–173.
2011.PubMed/NCBI
|
|
120
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
121
|
Davidson BL and McCray PB: Current
prospects for RNA interference-based therapies. Nat Rev Genet.
12:329–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Ben-David-Naim M, Dagan A, Grad E, Aizik
G, Nordling-David MM, Morss Clyne A, Granot Z and Golomb G:
Targeted siRNA nanoparticles for mammary carcinoma therapy. Cancers
(Basel). 11:4422019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Yang L, Zhao W, Zuo WS, Wei L, Song XR,
Wang XW, Zheng G and Zheng MZ: Silencing of osteopontin promotes
the radiosensitivity of breast cancer cells by reducing the
expression of hypoxia inducible factor 1 and vascular endothelial
growth factor. Chin Med J (Engl). 125:293–299. 2012.PubMed/NCBI
|
|
124
|
Wang F, Fu K, Wang Y, Pan C, Wang X, Liu
Z, Yang C, Zheng Y, Li X, Lu Y, et al: Small-molecule agents for
cancer immunotherapy. Acta Pharm Sin B. 14:905–952. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sharma P, Kumar S and Kundu GC:
Transcriptional regulation of human osteopontin promoter by histone
deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol
Cancer. 9:1782010. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Kumar S, Patil HS, Sharma P, Kumar D,
Dasari S, Puranik VG, Thulasiram HV and Kundu GC: Andrographolide
inhibits osteopontin expression and breast tumor growth through
down regulation of PI3 kinase/akt signaling pathway. Curr Mol Med.
12:952–966. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Matsuura M, Suzuki T and Saito T:
Osteopontin is a new target molecule for ovarian clear cell
carcinoma therapy. Cancer Sci. 101:1828–1833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Lv J, Shao Q, Wang H, Shi H, Wang T, Gao
W, Song B, Zheng G, Kong B and Qu X: Effects and mechanisms of
curcumin and basil polysaccharide on the invasion of SKOV3 cells
and dendritic cells. Mol Med Rep. 8:1580–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Nimjee SM, White RR, Becker RC and
Sullenger BA: Aptamers as therapeutics. Annu Rev Pharmacol Toxicol.
57:61–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
He S, Du Y, Tao H and Duan H: Advances in
aptamer-mediated targeted delivery system for cancer treatment. Int
J Biol Macromol. 238:1241732023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Talbot LJ, Mi Z, Bhattacharya SD, Kim V,
Guo H and Kuo PC: Pharmacokinetic characterization of an RNA
aptamer against osteopontin and demonstration of in vivo efficacy
in reversing growth of human breast cancer cells. Surgery.
150:224–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ahmed M and Kundu GC: Osteopontin
selectively regulates p70S6K/mTOR phosphorylation leading to
NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast
cancer cells. Mol Cancer. 9:1012010. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ahmed M, Behera R, Chakraborty G, Jain S,
Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, et al:
Osteopontin: A potentially important therapeutic target in cancer.
Expert Opin Ther Targets. 15:1113–1126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chiou J, Chang YC, Tsai HF, Lin YF, Huang
MS, Yang CJ and Hsiao M: Follistatin-like protein 1 inhibits lung
cancer metastasis by preventing proteolytic activation of
osteopontin. Cancer Res. 79:6113–6125. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Salih E, Ashkar S, Gerstenfeld LC and
Glimcher MJ: Identification of the phosphorylated sites of
metabolically 32P-labeled osteopontin from cultured chicken
osteoblasts. J Biol Chem. 272:13966–13973. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Peraramelli S, Zhou Q, Zhou Q, Wanko B,
Zhao L, Nishimura T, Leung TH, Mizuno S, Ito M, Myles T, et al:
Thrombin cleavage of osteopontin initiates osteopontin's
tumor-promoting activity. J Thromb Haemost. 20:1256–1270. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zou Y, Sun X, Wang Y, Yan C, Liu Y, Li J,
Zhang D, Zheng M, Chung RS and Shi B: Single siRNA nanocapsules for
effective siRNA brain delivery and glioblastoma treatment. Adv
Mater. 32:e20004162020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bansal I, Pandey AK and Ruwali M:
Small-molecule inhibitors of kinases in breast cancer therapy:
Recent advances, opportunities, and challenges. Front Pharmacol.
14:12445972023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lu C, Liu Z, Klement JD, Yang D, Merting
AD, Poschel D, Albers T, Waller JL, Shi H and Liu K: WDR5-H3K4me3
epigenetic axis regulates OPN expression to compensate PD-L1
function to promote pancreatic cancer immune escape. J Immunother
Cancer. 9:e0026242021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu
JL, Li CW, Lim SO, Sheng YY, Zhang Y, et al: Disruption of
tumour-associated macrophage trafficking by the osteopontin-induced
colony-stimulating factor-1 signalling sensitises hepatocellular
carcinoma to anti-PD-L1 blockade. Gut. 68:1653–1666. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Saleh S, Thompson DE, McConkey J, Murray P
and Moorehead RA: Osteopontin regulates proliferation, apoptosis,
and migration of murine Claudin-low mammary tumor cells. BMC
Cancer. 16:3592016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Cho W-Y, Hong SH, Singh B, Islam MA, Lee
S, Lee AY, Gankhuyag N, Kim JE, Yu KN, Kim KH, et al: Suppression
of tumor growth in lung cancer xenograft model mice by
poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. Eur J
Pharm Biopharm. 94:450–462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bhattacharya SD, Garrison J, Guo H, Mi Z,
Markovic J, Kim VM and Kuo PC: Micro-RNA-181a regulates
osteopontin-dependent metastatic function in hepatocellular cancer
cell lines. Surgery. 148:291–297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Mason CK, McFarlane S, Johnston PG, Crowe
P, Erwin PJ, Domostoj MM, Campbell FC, Manaviazar S, Hale KJ,
El-Tanani M, et al: Agelastatin A: A novel inhibitor of
osteopontin-mediated adhesion, invasion, and colony formation. Mol
Cancer Ther. 7:548–558. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Dai J, Li B, Shi J, Peng L, Zhang D, Qian
W, Hou S, Zhao L, Gao J, Cao Z, et al: A humanized Anti-osteopontin
antibody inhibits breast cancer growth and metastasis in vivo.
Cancer Immunol Immunother. 59:355–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Teramoto H, Castellone MD, Malek RL,
Letwin N, Frank B, Gutkind JS and Lee NH: Autocrine activation of
an osteopontin-CD44-Rac pathway enhances invasion and
transformation by H-RasV12. Oncogene. 24:489–501. 2005. View Article : Google Scholar : PubMed/NCBI
|
